MB-077-0015 | 10X RIPA Lysis Buffer Clinisciences

Specifications for 10X RIPA Lysis Buffer

Product Details

Description: 10X RIPA Lysis Buffer - MB-077-0015

Synonyms: 10X RIPA Lysis Buffer, RIPA (Radio-Immunoprecipitation Assay) Lysis Buffer

Target Details

Purity/Specificity: This product was aseptically filtered through a Millipore 0.22 micron filter into clean, pre-sterilized containers. The product was tested on trypticase soy agar for 24 hours, 48 hours and 72 hours and was found to be negative for bacteria.

Application Details

Tested / Suggested Applications: WB, ChIP, IP, Other - View References

Application Note: This product is 10X concentrated stock solution. Dilute to 1X prior to use. 1X RIPA Lysis Buffer is intended for the extraction of cellular proteins for the efficient lysis of cells and solubilization of protein, while minimizing protein degradation and maintaining protein immunoreactivity and biological activity. We recommend using 1.0 ml of RIPA Lysis Buffer to lyse 0.5 to 5 x 10E7 adherent mammalian cells. This buffer contains ionic detergents and may not be suitable for kinase enzymes, if these enzymes are easily denatured. Do not add phosphatase inhibitors when preparing lysates for phosphatase assays. 1X RIPA lysis buffer consists of 50 mM Tris HCl, 150 mM NaCl, 1.0% (v/v) IGEPAL® CA-630, 0.5% (w/v) Sodium Deoxycholate, 1.0 mM EDTA, 0.1% (w/v) SDS and 0.01% (w/v) sodium azide at a pH of 7.4. This buffer was meticulously prepared using ultra pure reagents dissolved in highly polished pharmaceutical grade deionized water. Protease and phosphatase inhibitors are recommended but not included in product composition. Recommended final concentrations of protease inhibitors: 1.0 mM Phenylmethylsulfonyl fluoride (PMSF) 10 µM Leupeptin 0.1 µM Aprotinin 1.0 µM Pepstatin Recommended final concentrations of phosphatase inhibitors: 1.0 mM Na3VO4 1.0 mM NaF

Formulation

Concentration: 10X

Buffer: See application note.

Preservative: 0.01% (w/v) Sodium Azide

Stabilizer: None

Shipping & Handling

Shipping Condition: Ambient

Storage Condition: Store container at room temperature (18° to 26° C) prior to opening. Protect from light (store in the dark).

Expiration: Expiration date is six (6) months from date of receipt.

Background

RIPA (Radio-Immunoprecipitation Assay) Lysis Buffer enables rapid, efficient cell lysis and solubilization of proteins from both adherent and suspension cultured mammalian cells. It has long been a widely used lysis and wash buffer for small-scale affinity pull-down applications, such as immunoprecipitation, since most antibodies and protein antigens are not adversely affected by the components of this buffer. In addition, RIPA Lysis Buffer minimizes non-specific protein-binding interactions to keep background low, while allowing most specific interactions to occur, enabling studies of relevant protein-protein interactions. The following RIPA Lysis Buffer components have the following effects: Tris-HCl is a buffering agent prevents protein denaturation, NaCl is a salt that prevents non-specific protein aggregation, IGEPAL is a non-ionic detergent to extract proteins; Na-deoxycholate and SDS are ionic detergents to extract proteins; and sodium azide is a bacteriostatic agent added to retard bacterial growth. RIPA Lysis Buffer is supplied as a ready-to-use solution that requires no preparation. We suggest that the user add protease and phosphatase inhibitors not included with this product prior to use.

References (24)

Jeong GH et al. (2025). A New Class of Hybrid Anti-inflammatory Agents of Silibinin A Modified Using Gamma Irradiation. Chem Pharm Bull (Tokyo).

Applications

WB/IB/PCA

PubMed

Kim YH et al. (2025). Reduction of Low-Density Lipoprotein Cholesterol by Mesenchymal Stem Cells in a Mouse Model of Exogenous Cushing's Syndrome. Tissue Eng Regen Med.

Applications

WB/IB/PCA

PubMed

Bhalla M et al. (2025). SIRT2 and ALDH1A1 as critical enzymes for astrocytic GABA production in Alzheimer's disease. Mol Neurodegener.

Applications

WB/IB/PCA

PubMed

Nesbitt NM et al. (2025). Small molecule BLVRB redox inhibitor promotes megakaryocytopoiesis and stress thrombopoiesis in vivo. Nat Commun.

Applications

WB/IB/PCA

PubMed

Hyun J et al. (2025). Strengthening the cellular function of dermal fibroblasts and dermal papilla cells using nanovesicles extracted from stem cells using blue light-based photobiomodulation technology. Biomatter Sci.

Applications

WB/IB/PCA

PubMed

Song Y et al. (2025). Unveiling aging heterogeneities in human dermal fibroblasts via nanosensor chemical cytometry. Nat Commun.

Applications

WB/IB/PCA

PubMed

Kim YJ, et al. (2025). Synergistic Ion-Releasing Nanoparticles as a Therapeutic Platform for Modulating Adult Stem Cell Activity in Wound Healing. Biomater Res.

Applications

WB/IB/PCA

PubMed

Kim JU et al. (2025). Gold Nanoturf-Mediated Wireless Photothermal Upregulation of Human Adipose-Derived Stem Cell Spheroids for Synergistic Skin-Wound Closure. Adv Sci (Weinh).

Applications

WB/IB/PCA

PubMed

Lee YB et al. (2024). Enhancing skin regeneration efficacy of human dermal fibroblasts using carboxymethyl cellulose-coated biodegradable polymer. Tissue Eng Regen Med.

Applications

WB/IB/PCA

PubMed

Peltier S et al. (2024). In vitro effects of wound-dressings on key wound healing properties of dermal fibroblasts. Exp Dermatol.

Applications

WB/IB/PCA

PubMed

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.